These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 16617018

  • 1. Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
    Kainuma M, Kasuga J, Hosoda S, Wakabayashi K, Tanatani A, Nagasawa K, Miyachi H, Makishima M, Hashimoto Y.
    Bioorg Med Chem Lett; 2006 Jun 15; 16(12):3213-8. PubMed ID: 16617018
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
    Downie MM, Sanders DA, Maier LM, Stock DM, Kealey T.
    Br J Dermatol; 2004 Oct 15; 151(4):766-75. PubMed ID: 15491415
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand.
    Takahashi M, Kanayama T, Yashiro T, Kondo H, Murase T, Hase T, Tokimitsu I, Nishikawa J, Sato R.
    Biochem Biophys Res Commun; 2008 Aug 01; 372(3):395-9. PubMed ID: 18457666
    [Abstract] [Full Text] [Related]

  • 5. Hypolipidemia induced by PPARalpha agonists: HNF-4alpha as an alternative to PPARalpha.
    Bar-Tana J.
    Curr Opin Investig Drugs; 2004 Sep 01; 5(9):941-6. PubMed ID: 15503648
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC.
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar 01; 296(3):G543-52. PubMed ID: 19136377
    [Abstract] [Full Text] [Related]

  • 8. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
    Pellicciari R, Costantino G, Camaioni E, Sadeghpour BM, Entrena A, Willson TM, Fiorucci S, Clerici C, Gioiello A.
    J Med Chem; 2004 Aug 26; 47(18):4559-69. PubMed ID: 15317466
    [Abstract] [Full Text] [Related]

  • 9. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
    Pellicciari R, Gioiello A, Costantino G, Sadeghpour BM, Rizzo G, Meyer U, Parks DJ, Entrena-Guadix A, Fiorucci S.
    J Med Chem; 2006 Jul 13; 49(14):4208-15. PubMed ID: 16821780
    [Abstract] [Full Text] [Related]

  • 10. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L.
    Trends Mol Med; 2007 Jul 13; 13(7):298-309. PubMed ID: 17588816
    [Abstract] [Full Text] [Related]

  • 11. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators.
    Honório KM, Garratt RC, Polikarpov I, Andricopulo AD.
    J Mol Graph Model; 2007 Mar 13; 25(6):921-7. PubMed ID: 17055759
    [Abstract] [Full Text] [Related]

  • 12. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
    Nicolaou KC, Evans RM, Roecker AJ, Hughes R, Downes M, Pfefferkorn JA.
    Org Biomol Chem; 2003 Mar 21; 1(6):908-20. PubMed ID: 12929628
    [Abstract] [Full Text] [Related]

  • 13. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
    Miyachi H.
    IDrugs; 2004 Aug 21; 7(8):746-54. PubMed ID: 15334308
    [Abstract] [Full Text] [Related]

  • 14. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R, Golla R, Ma Z, Zhang H, O'Malley K, Lippy J, Cheng L, Mookhtiar K, Farrelly D, Zhang L, Hariharan N, Cheng PT.
    Anal Biochem; 2007 Apr 15; 363(2):263-74. PubMed ID: 17335769
    [Abstract] [Full Text] [Related]

  • 15. Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes.
    Monte MJ, Rosales R, Macias RI, Iannota V, Martinez-Fernandez A, Romero MR, Hofmann AF, Marin JJ.
    Am J Physiol Gastrointest Liver Physiol; 2008 Jul 15; 295(1):G54-G62. PubMed ID: 18467501
    [Abstract] [Full Text] [Related]

  • 16. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P, Hierro L, Jara P, Alvarez L.
    Am J Physiol Gastrointest Liver Physiol; 2009 May 15; 296(5):G1119-29. PubMed ID: 19228886
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M, Makishima M, Hashimoto Y, Miyachi H.
    Bioorg Med Chem; 2007 Apr 01; 15(7):2587-600. PubMed ID: 17292610
    [Abstract] [Full Text] [Related]

  • 18. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
    Journe F, Laurent G, Chaboteaux C, Nonclercq D, Durbecq V, Larsimont D, Body JJ.
    Breast Cancer Res Treat; 2008 Jan 01; 107(1):49-61. PubMed ID: 17333335
    [Abstract] [Full Text] [Related]

  • 19. Screening of novel nuclear receptor agonists by a convenient reporter gene assay system using green fluorescent protein derivatives.
    Suzuki T, Nishimaki-Mogami T, Kawai H, Kobayashi T, Shinozaki Y, Sato Y, Hashimoto T, Asakawa Y, Inoue K, Ohno Y, Hayakawa T, Kawanishi T.
    Phytomedicine; 2006 Jun 01; 13(6):401-11. PubMed ID: 16716909
    [Abstract] [Full Text] [Related]

  • 20. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
    Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D.
    Cancer Res; 2006 Oct 15; 66(20):10120-6. PubMed ID: 17047076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.